AR078163A1 - Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes - Google Patents

Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes

Info

Publication number
AR078163A1
AR078163A1 ARP100103301A ARP100103301A AR078163A1 AR 078163 A1 AR078163 A1 AR 078163A1 AR P100103301 A ARP100103301 A AR P100103301A AR P100103301 A ARP100103301 A AR P100103301A AR 078163 A1 AR078163 A1 AR 078163A1
Authority
AR
Argentina
Prior art keywords
diabetes
halogen
prevention
treatment
alkoxy
Prior art date
Application number
ARP100103301A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR078163A1 publication Critical patent/AR078163A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/041,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/061,3-Thiazines; Hydrogenated 1,3-thiazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP100103301A 2009-09-11 2010-09-09 Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes AR078163A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09170126 2009-09-11
EP09172068 2009-10-02

Publications (1)

Publication Number Publication Date
AR078163A1 true AR078163A1 (es) 2011-10-19

Family

ID=43086098

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103301A AR078163A1 (es) 2009-09-11 2010-09-09 Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes

Country Status (10)

Country Link
US (3) US20110065695A1 (OSRAM)
EP (1) EP2475658A1 (OSRAM)
JP (1) JP2013503838A (OSRAM)
CN (1) CN102482268B (OSRAM)
AR (1) AR078163A1 (OSRAM)
CA (1) CA2771374A1 (OSRAM)
IN (1) IN2012DN01233A (OSRAM)
SG (1) SG179034A1 (OSRAM)
TW (1) TW201114765A (OSRAM)
WO (1) WO2011029803A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416603C9 (ru) 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
US8653067B2 (en) * 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
AU2008245082B8 (en) * 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
NZ589590A (en) 2008-06-13 2012-05-25 Shionogi & Co Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
CN102186841A (zh) * 2008-10-22 2011-09-14 盐野义制药株式会社 具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
JP5816630B2 (ja) 2010-10-29 2015-11-18 塩野義製薬株式会社 ナフチリジン誘導体
EP2634188A4 (en) 2010-10-29 2014-05-07 Shionogi & Co FUSIONED AMINODIHYDROPYRIMIDINE DERIVATIVE
WO2012138734A1 (en) 2011-04-07 2012-10-11 Merck Sharp & Dohme Corp. C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
BR112013026341A2 (pt) 2011-04-13 2019-09-24 Merck Sharp & Dohe Corp composto, composição farmacêutica, e, método para tratar, prevenir e/ou atrasar o início de uma doença ou patologia
CN103596939A (zh) * 2011-04-13 2014-02-19 默沙东公司 作为bace抑制剂的5-取代的亚氨基噻嗪类及其单和二氧化物、组合物及其应用
US20140235626A1 (en) 2011-04-26 2014-08-21 Shionogi & Co., Ltd. Pyridine derivatives and a pharmaceutical composition for inhibiting bace1 containing them
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8927535B2 (en) * 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
BR112014004181A2 (pt) 2011-08-22 2017-06-13 Merck Sharp & Dohme composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
JP2015514073A (ja) 2012-03-20 2015-05-18 エラン ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニー スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンbace阻害剤、ならびにその組成物および使用
WO2013148130A1 (en) 2012-03-29 2013-10-03 Oklahoma Medical Research Foundation Inhibition of memapsin 1 cleavage in the treatment of diabetes
JP6251249B2 (ja) * 2012-05-24 2017-12-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Bace1阻害薬としての5−アミノ[1,4]チアジン類
JP2015520202A (ja) 2012-06-20 2015-07-16 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Lpar拮抗薬としてのn−アルキルトリアゾール化合物
WO2014059185A1 (en) 2012-10-12 2014-04-17 Amgen Inc. Amino - dihydrothiazine and amino - dioxido dihydrothiazine compounds as beta-secretase antagonists and methods of use
JP2016501827A (ja) 2012-10-24 2016-01-21 塩野義製薬株式会社 Bace1阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体
WO2014078314A1 (en) 2012-11-15 2014-05-22 Amgen Inc. Amino-oxazine and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use
WO2014134341A1 (en) 2013-03-01 2014-09-04 Amgen Inc. Perfluorinated 5,6-dihydro-4h-1,3-oxazin-2-amine compounds as beta-secretase inhibitors and methods of use
BR112015021336A2 (pt) 2013-03-08 2017-07-18 Amgen Inc compostos 1,3-oxazin-2-amina fundidos ciclopropil perfluorados como inibidores de beta-secretase e métodos de uso
AU2015301028B2 (en) 2014-08-08 2019-09-26 Amgen Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
PE20171349A1 (es) 2015-03-20 2017-09-13 Hoffmann La Roche Inhibidores de bace1
WO2017024180A1 (en) 2015-08-06 2017-02-09 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
MA54100A (fr) 2016-12-15 2021-10-20 Amgen Inc Dérivés de thiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MA54101A (fr) 2016-12-15 2021-10-27 Amgen Inc Dérivés de thiazine et d'oxazine bicycliques en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
US10947223B2 (en) 2016-12-15 2021-03-16 Amgen Inc. Substituted oxazines as beta-secretase inhibitors
MA50007A (fr) 2016-12-15 2021-04-07 Amgen Inc Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MX386618B (es) 2016-12-15 2025-03-19 Amgen Inc Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2416603C9 (ru) * 2005-10-25 2012-06-20 Сионоги Энд Ко., Лтд. Производные аминодигидротиазина
US8653067B2 (en) * 2007-04-24 2014-02-18 Shionogi & Co., Ltd. Pharmaceutical composition for treating Alzheimer's disease
AU2008245082B8 (en) * 2007-04-24 2012-09-13 Shionogi & Co., Ltd. Aminodihydrothiazine derivatives substituted with a cyclic group
MX2010008347A (es) * 2008-02-18 2010-11-12 Hoffmann La Roche Derivados de 4,5-dihidro-oxazol-2-ilamina.
WO2010063718A1 (en) * 2008-12-02 2010-06-10 ETH Zürich Screening assay for metabolic disease therapeuticals

Also Published As

Publication number Publication date
WO2011029803A1 (en) 2011-03-17
CA2771374A1 (en) 2011-03-17
SG179034A1 (en) 2012-04-27
IN2012DN01233A (OSRAM) 2015-05-15
CN102482268A (zh) 2012-05-30
JP2013503838A (ja) 2013-02-04
US20140221360A1 (en) 2014-08-07
CN102482268B (zh) 2014-11-26
EP2475658A1 (en) 2012-07-18
US20130096107A1 (en) 2013-04-18
US20110065695A1 (en) 2011-03-17
TW201114765A (en) 2011-05-01

Similar Documents

Publication Publication Date Title
AR078163A1 (es) Utilizacion de aminodihidrotiazinas para el tratamiento o prevencion de la diabetes
AR079334A1 (es) Derivados de oxazin amino
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR074021A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
AR066020A1 (es) Derivados de imidazolidin-2, 4-diona, una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de parp-1.
AR054799A1 (es) Derivados de oxindol
AR073369A1 (es) Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR079327A1 (es) Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida
AR066583A1 (es) Derivados de 3,3-espiroindolinona
ES2530943T3 (es) Derivados de la cromenona con actividad antitumoral
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR059957A1 (es) DERIVADOS DE ESPIROINDOLINONA, MÉTODOS PARA SU PREPARACIoN, UNA COMPOSICIoN FARMACÉUTICA QUE LOS CONTIENE Y SU USO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DEL CÁNCER.
PE20130155A1 (es) Derivados de ariletinilo
AR055592A1 (es) Derivados de 2-amino-5-cicloalquil-hidantoina como moduladores y/o inhibidores de la beta-secretasa(bace)
AR063988A1 (es) Derivados heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
BRPI0909731A2 (pt) derivados de carbazol inibidores de hsp90, composições que os contêm e a respectiva utilização
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
BRPI0718966B8 (pt) composto, composição farmacêutica, inibidor plk1 e agente antitumoral
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR063602A1 (es) Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos.
CU23761B7 (es) Nuevos derivados de diosmetina, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR067665A1 (es) Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
AR069607A1 (es) Inhibidores de la estearoil-coa desaturasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure